

TODAY IN WASHINGTON - JUNE 18, 2020: COVID-19 UPDATES

THURSDAY, JUNE 18 UPDATE

Note – Our Federal Advocacy Team is dedicated to providing frequent COVID-19 updates as they develop. We believe this is the most up-to-date information available at this time. These updates along with other resources can be found on the [COVID-19 Resource Center page of Hall Render's website](#).

To learn more about how our services can help your organization, click [here](#).

CONGRESSIONAL OUTLOOK

- Yesterday, the Senate Health Education Labor and Pensions Committee held a hearing to consider which telehealth expansion provisions should be continued once the coronavirus public health emergency ends. Most agreement was reached over continuing to pay doctors for telehealth visits regardless of the patient's location and keeping the new types of covered services eligible for reimbursement. Although the cost of expanding telehealth has always been the biggest hurdle for Congress, the committee's chairman, Sen. Lamar Alexander, indicated that coronavirus expansions provisions could be included in health care-related legislation that will come up later this year.

DOL ISSUES OSHA GUIDANCE FOR EMPLOYERS ON RE-OPENING NON-ESSENTIAL BUSINESSES

- The Department of Labor's Occupational Safety and Health Administration issued [guidance](#) to assist employers re-opening non-essential businesses.

HHS AWARDS FUNDS TO TRAIN HEALTH WORKFORCE

- The Health Resources and Services Administration [announced](#) the distribution of \$107.2 million to 310 recipients to increase the health workforce in rural and underserved communities.

FROM THE FDA

- The FDA posted a new web page: [Adverse Event Reporting for Medical Devices Under Emergency Use Authorization \(EUA\) or Discussed in COVID-19-Related Guidance Documents](#).
- The FDA [announced](#) they will hold a webinar on "Importing Respirators for Health Care Personnel Use during COVID-19 Pandemic." The webinar will be **Tuesday, June 23 at 12:00 PM EDT**.
- The FDA published: [Statistical Considerations for Clinical Trials During the COVID-19 Public Health Emergency Guidance for Industry](#).

CONTACT INFORMATION

For more information on how our [Federal Legislative and Regulatory Advocacy team](#) can help your organization lobby Congress to include beneficial provisions in future legislation, track the course of other legislation, receive up-to-the-minute information on regulations and agency guidance or even get a simple question answered by an agency employee, please contact:

- John Williams III at (202) 370-9585 or jwilliams@hallrender.com;
- Andrew Coats at (202) 370-9587 or acoats@hallrender.com; or
- Abby Kaericher at (202) 780-2989 or akaericher@hallrender.com.

Hall Render's attorneys and professionals continue to maintain the most up-to-date information and resources at our [COVID-19 Resource page](#), through our 24/7 COVID-19 Hotline at (317) 429-3900 or by contacting your regular Hall Render attorney.

Hall Render blog posts and articles are intended for informational purposes only. For ethical reasons, Hall Render attorneys cannot—outside of an attorney-client relationship—answer specific questions that would be legal advice.